Company type | Public |
---|---|
Industry | |
Predecessors | |
Founded | 1956 |
Headquarters | Waltham, Massachusetts, U.S. |
Area served | Worldwide |
Key people | |
Products | Analytical/other equipment and instruments, laboratory reagents and consumables, science software and services—for research, discovery, analysis, and manufacturing (incl. pharmaceutical and diagnostic products) |
Revenue | US$42.86 billion (2023) |
US$6.859 billion (2023) | |
US$5.955 billion (2023) | |
Total assets | US$98.73 billion (2023) |
Total equity | US$46.74 billion (2023) |
Number of employees | c. 122,000 (2023) |
Website | www |
Footnotes /references Financials as of December 31,2023 [update] [1] |
Thermo Fisher Scientific Inc. is an American-headquartered life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), [2] Alfa Aesar (2015), [3] Affymetrix (2016), [4] FEI Company (2016), [5] BD Advanced Bioprocessing (2018), [6] and PPD (2021). [7]
As of 2023 [update] , the company had a market capitalization of $202 billion. It ranked 97th on the Fortune 500 list based on its 2022 annual revenue of US$44.92 billion. [8]
Thermo Electron was co-founded in 1956 by George N. Hatsopoulos and Peter M Nomikos. Hatsopoulos received a PhD from MIT in mechanical engineering and Nomikos was a Harvard Business School graduate. [9] The company focused on providing analytical and laboratory products, and had revenues of over $2 billion in 2004. [10]
Fisher Scientific was founded in 1902 by Chester G. Fisher from Pittsburgh. [11] [12] It focused on providing laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety, and education. [13]
On May 8, 2006, Thermo Electron and Fisher Scientific announced that they would merge in a tax-free, stock-for-stock exchange; the merged company was named Thermo Fisher Scientific, and had about 30,000 employees, and reported US$9 billion in combined revenue. [14] On November 9, 2006, the companies announced that the merger had been completed. [15] However, the Federal Trade Commission ruled that this acquisition was anti-competitive regarding centrifugal evaporators, requiring Fisher to divest Genevac. [16] In April 2007, Genevac was sold to Riverlake Partners LLC [17] and the merger closed with FTC approval. [18]
The company's products are sold under the brand names of Thermo Scientific, Fisher Scientific, and several other recognized brand names (e.g. Applied Biosystems, Invitrogen, Patheon, PPD, and Nalgene). According to company figures, as of 2007, 46% of its sales were in life sciences, 20% in healthcare, and 34% in industrial/environmental and safety. [13]
In 1990, Thermo Fisher Scientific (then known as Thermo Instrument Systems) acquired mass spectrometer manufacturer Finnigan Instrument Corporation. [19]
In 2003, the company (then Fisher Scientific International) acquired Perbio Science, a transaction that included brands such as Pierce Biotechnology, HyClone and Endogen. [20] In April 2006, BioImage was acquired by Thermo Fisher Scientific. [21] The merger was complete in November 2006, and technology transfer to a US site was completed during 2007 and 2008. [22] [23] BioImage was established in 1993 as a drug discovery research unit led by Ole Thastrup within Novo Nordisk, from which it spun out of in 1999. It had specialized in developing and selling proprietary bioassays to biopharmaceutical companies and research institutions. It made broad patents covering Enhanced GFP (EGFP), GFP-based biosensors and any genetically encoded protein fusion to a luminophore, with subsequent monitoring of the protein's translocation within a cell as the primary readout for drug discovery assays. [24]
In December 2010, Thermo Fisher Scientific announced its acquisition of Dionex for $2.1 billion. [25]
In May 2011, Thermo Fisher Scientific Inc. bought Phadia to expand into the testing of allergies and autoimmune diseases for €2.47 billion ($3.5 billion) in cash. [26]
In April 2013, after a competitive bidding with Hoffmann-La Roche, [27] Thermo Fisher acquired Life Technologies Corporation for US$13.6 billion in a deal, adding further service lines related to advanced DNA sequencing and genetic testing. [28] Life Technologies was originally formed in 2008 through a $6.7B merger of Invitrogen, a cell therapy, and Applied Biosystems. [29] The company also acquired GIBCO (Grand Island Biological Company) as part of the Life Technologies acquisition. [30]
In February 2015, the company announced it would acquire Advanced Scientifics for $300 million in a cash-deal. ASI designs manufactures, and delivers technologies used in bioprocessing. [31] In June 2015, the company announced its intention to acquire Alfa Aesar, a global manufacturer of research chemicals for $405 million [32] from Johnson Matthey, and the acquisition was completed at the end of September [33]
In January 2016, the company announced it would acquire Affymetrix for $1.3 billion. [34] On May 27, 2016, the company announced it would acquire FEI Company for $4.2 billion, a manufacturer of electron microscopes. [35] [36] This acquisition is anticipated to close in early 2017 and will contribute to the growth of Thermo's Analytical Instruments business group. [37] In November the company announced it would acquire MTI-GlobalStem, a previously privately held company that develops reagents for cell transfection, neurobiology and stem cell research. [38]
In February 2017, the company acquired Finesse Solutions, Inc., developer of scalable control automation systems and software for bioproduction after receiving early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. [39] The transaction was completed a day later. [40] In March, the company announced it would acquire Core Informatics, provider of cloud-based platforms supporting scientific data management. [41] In August, the company acquired Patheon, a contract development and manufacturing organization serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. [42] As of 2017, the company had revenues of $20.9 billion, and was a Fortune 500 company. [43]
In September 2018, Thermo Fisher Scientific announced it had signed a definitive agreement with Becton, Dickinson and Company (BDX) to acquire their Advanced Bioprocessing business. This BD business had annualized revenue of approximately $100 million; as of October 16, 2018, it had been integrated into Thermo Fisher's Life Sciences Solutions Segment. [44]
In March 2019, Thermo Fisher Scientific announced its entry into the gene therapy manufacturing market with a $1.7 billion cash acquisition for Brammer Bio. [45] [46] [47] In May 2019, Thermo Fisher Scientific partnered with MMJ International Holdings to manufacture drug products developed by MMJ for the treatment of multiple sclerosis and Huntington's disease. [48] [49] In June, the business announced it would acquire mass spectrometry software provider, HighChem. [50]
In March 2020, Thermo Fisher Scientific agreed to purchase Qiagen, a molecular diagnostics company, for $10.1 billion. [51] In July, the offer for Qiagen was raised from €39 to €43 per share (€11.3 billion in total). [52] [53] On August 13, the company announced that its offer to acquire all of the ordinary share had lapsed, and it terminated the acquisition agreement. [54]
In August 2020, Thermo Fisher Scientific opened its new Lenexa facility aimed at boosting the production and manufacturing of COVID-19 testing supplies. [55] In December the business announced it would acquire Phitonex, Inc. [56]
In January 2021, Thermo Fisher Scientific announced it had acquired Belgium-based viral vector manufacturer, Henogen SA, from Groupe Novasep SAS for €725 million in cash [57] [58] [59] and point-of-care molecular diagnostics provider Mesa Biotech, Inc. for up to $550 million. [60] [61] [62]
In April 2021, Thermo Fisher Scientific announced the acquisition of PPD, Inc., a contract research organization, for a total cash purchase price of $17.4 billion-plus the assumption of approximately $3.5 billion of net debt. PPD generated $4.7 billion in revenue during FY 2020, and this transaction, which values their company at approximately $20.9 billion. [63] In November, the business announced it would acquire PharmaFluidics and its μPAC range of micro-chip-based chromatography products. [64]
In January 2022, Thermo Fisher Scientific acquired PeproTech, a developer and manufacturer of recombinant proteins, for $1.85 billion. PeproTech became part of Thermo Fisher’s biosciences business and was integrated into the Life Sciences Solutions Segment. [65]
In October 2022, the company agreed to buy British diagnostics firm, The Binding Site Group, in an all-cash deal for US$2.6 billion from Nordic Capital. [66] [67] The acquisition completed in January 2023. [68]
In July 2023, the business announced it would acquire CorEvitas, LLC from Audax Private Equity for more than $900 million in cash. [69] In August 2023, it was announced Thermo Fisher had completed the acquisition for $912.5 million (in cash). [70]
In October 2023, Thermo Fisher Scientific acquired Olink Holding for $3.1 billion. [71]
Marc N. Casper is chairman, president and chief executive officer of Thermo Fisher Scientific. [79] He first joined Thermo Electron in December 2001 as Vice President of the Life and Laboratory Sciences segment. In November 2006, when Thermo Electron and Fisher Scientific merged to form Thermo Fisher Scientific, Casper was named executive vice president of the company and president of the Analytical Technologies Group. He became president and CEO in 2009. [80]
In September 2017, Thermo Fisher Scientific signed an agreement with the Institute of Pathology Heidelberg (IPH) to establish its Center of Molecular Pathology at Heidelberg University Hospital as the newest member of the Next Generation Sequencing Companion Dx Center of Excellence Program (COEP). The initiative focuses on establishing strategic collaborations with leading, European-based organizations that can lead studies using Thermo Fisher's Oncomine portfolio of research panels destined for development as companion diagnostics to help drive precision oncology in the region. [81]
In 2021, Thermo Fisher announced the construction of a cell therapy development, manufacturing and collaboration center in cooperation with University of California, San Francisco on the school's Mission Bay campus. [82]
In February 2022, Thermo Fisher Scientific announced a 15-year strategic collaboration agreement with Moderna, Inc. The collaboration was designed to scale up the manufacturing of Moderna’s COVID-19 vaccine and other investigational mRNA products. [83]
In May 2023, Thermo Fisher partnered with Pfizer, with plans to work together on expanding testing capabilities for lung and breast cancer patients. [84]
In November 2023, Thermo Fisher partnered with Flagship Pioneering, a biotechnology company. [85] Together, they plan to create companies in the biotechnology field. [86]
In March 2020, Thermo Fisher Scientific received emergency use authorization from the FDA for a test for SARS-CoV-2 to help mitigate the COVID-19 pandemic. [87] Thermo Fisher also partnered with its biopharma customers, including Pfizer and Moderna, to support the development and production of new mRNA-based COVID-19 vaccines. [88] [89]
In February 2019, Thermo Fisher Scientific announced that it would stop selling its equipment in Xinjiang. [90] In June 2020, Thermo Fisher Scientific was reported to sell its equipment to security services in China for use in what was alleged as part of a genetic surveillance program. [91] A report from the Australian Strategic Policy Institute found that Thermo Fisher Scientific collaborated with the Chinese Ministry of Public Security to develop a Huaxia PCR amplification kit specifically to identify the genotypes of Uyghur, Tibetan and Hui ethnic minorities. [92] In June 2021, The New York Times reported that, despite bans, Thermo Fisher Scientific equipment continued to be sold to police in Xinjiang. [93]
In 2022, following reports that Thermo Fisher Scientific had sold products to police in the Tibet Autonomous Region, [94] the Inter-Parliamentary Alliance on China called on governments to "investigate and suspend commercial activities with companies providing the PRC government with technologies to carry out biometric surveillance in the Uyghur Region, Tibet and elsewhere in the PRC, including the PRC state backed BGI Group and US firm Thermo Fisher." [95] Thermo Fisher Scientific subsequently halted sales of DNA collection kits in Tibet. [96]
In October 2021 the estate of Henrietta Lacks sued to get past and future payment for the alleged and widely known unauthorized sale by Thermo Fisher Scientific of her HeLa cells which are essential in many types of research. [97] Over 50 million tons of her cells have been produced and used in over 60,000 scientific studies touching virtually every realm of medicine, including the development of polio vaccines, gene mapping, in-vitro fertilization, and multitudes more. [98] [99] [100]
In May 2022, it was announced Thermo Fisher Scientific went to court to seek a dismissal of the lawsuit. [101] In late July 2023, with the motion to dismiss still outstanding, the court ordered the parties to attend a settlement conference. [102] [103] Soon after that, settlement of the suit, with undisclosed terms, was announced. [104]
In 2013, Opengate Capital Group LLC filed suit against Thermo Fisher Scientific for selling it a manufacturing plant controlled by a drug cartel. According to Opengate Capital, the company withheld important documents and pressured employees into concealing the presence of the gang. [105] [106]
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.
Affymetrix is now Applied Biosystems, a brand of DNA microarray products sold by Thermo Fisher Scientific that originated with an American biotechnology research and development and manufacturing company of the same name. The Santa Clara, California-based Affymetrix, Inc. now a part of Thermo Fisher Scientific was co-founded by Alex Zaffaroni and Stephen Fodor. Stephen Fodor and his group, based on their earlier development of methods to fabricate DNA microarrays using semiconductor manufacturing techniques.
Medtronic plc is an American-Irish medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.
Boston Scientific Corporation (BSC), headquartered in Marlborough, Massachusetts and incorporated in Delaware, is a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. Boston Scientific is widely known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. With the full acquisition of Cameron Health in June 2012, the company also became notable for offering a minimally invasive implantable cardioverter-defibrillator (ICD) which they call the EMBLEM subcutaneous implantable defibrillator (S-ICD).
Fisher Scientific International, Inc. was a laboratory supply and biotechnology company that provided products and services to the global scientific research and clinical laboratory markets until its merger with Thermo Electron in 2006, after which it became Thermo Fisher Scientific. The company offered products and services to over 350,000 customers located in approximately 150 countries including pharmaceutical and biotechnology companies, secondary and higher education institutions, hospitals and medical research institutions, and quality control, process control and research and development laboratories.
PerkinElmer, Inc., previously styled Perkin-Elmer, is an American global corporation that was founded in 1937 and originally focused on precision optics. Over the years it went into and out of several different businesses via acquisitions and divestitures; these included defense products, semiconductors, computer systems, and others. By the 21st century, PerkinElmer was focused in the business areas of diagnostics, life science research, food, environmental and industrial testing. Its capabilities include detection, imaging, informatics, and service. It produced analytical instruments, genetic testing and diagnostic tools, medical imaging components, software, instruments, and consumables for multiple end markets. PerkinElmer was part of the S&P 500 Index and operated in 190 countries.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in respectively Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer (CEO).
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.
FEI Company was an American company that designed, manufactured, and supported microscope technology. Headquartered in Hillsboro, Oregon, FEI had over 2,800 employees and sales and service operations in more than 50 countries around the world. Formerly listed on the NASDAQ, it is now a subsidiary of Thermo Fisher Scientific.
Dharmacon Inc., now known as Dharmacon, was founded in 1995 by Stephen Scaringe as Dharmacon Research to develop and commercialize a new technology for RNA oligonucleotide synthesis. Originally, the company's focus was to develop 2'-ACE RNA technology as the standard for RNA synthesis and to advance RNA oligo-dependent applications and technologies.
Life Technologies Corporation was a biotech company founded in November 2008 through a US $6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees and owned more than 3,600 licenses and patents.
Pharmaceutical Product Development (PPD) is a global contract research organization (CRO) providing comprehensive, integrated drug development, laboratory and lifecycle management services. In December 2021, PPD became a wholly owned subsidiary of Thermo Fisher Scientific.
Dionex Corporation is an American company based in Sunnyvale, California. It develops, manufactures, sells, and services analytical chromatography systems for separating, isolating, and identifying the components of chemical mixtures. Such equipment is used in pharmaceutical manufacturing, medical research, environmental monitoring, and food testing.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
{{cite web}}
: CS1 maint: archived copy as title (link)